{"product_id":"gpc3-bhn20152504","title":"GPC3","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis GenCefe mRNA encodes \u003cstrong\u003eGPC3\u003c\/strong\u003e, a membrane protein, tumor-associated antigens construct supplied for antibody screening, CAR T-cell target validation, and cell-based binding assays. The product is formulated as lyophilised, non-encapsulated RNA and is intended for use in cell-based research applications requiring transient protein expression with reduced immunogenicity.\u003c\/p\u003e\n\u003ch2\u003emRNA Construct Design\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ Cap:\u003c\/strong\u003e Cap1 (m7GpppNm) — co-transcriptionally added during in vitro transcription (IVT). Cap1 includes 2′-O-methylation at the first transcribed nucleotide, closely mimicking the cap structure found on endogenous mammalian mRNA and reducing recognition by innate immune sensors (e.g., IFIT1\/IFIT3).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eModified Nucleotides:\u003c\/strong\u003e 100% N1-methylpseudouridine (m1Ψ; N1-Me-Pseudo UTP) substitution for all uridine residues. m1Ψ modification reduces TLR7\/TLR8-mediated innate immune activation and PKR-driven translational suppression, resulting in improved protein expression in immunocompetent cells and primary cell types.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePoly(A) Tail:\u003c\/strong\u003e 100–120 nt — enzymatically polyadenylated. The poly(A) tail stabilises the 3′ terminus, supports poly(A)-binding protein (PABP) recruitment, and enhances ribosome recycling for efficient cap-dependent translation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 5′ UTR) — a well-characterised human UTR that supports efficient cap-dependent translation initiation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e3′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 3′ UTR) — provides post-transcriptional stability and modulates mRNA decay kinetics.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSignal Peptide:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein Tag:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCodon Optimisation:\u003c\/strong\u003e No (native human codon usage retained)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA Length:\u003c\/strong\u003e Provided upon order placement.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eForm:\u003c\/strong\u003e Lyophilised powder; reconstitute in DEPC-treated water as needed.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis mRNA is supplied as non-encapsulated, lyophilised powder. Delivery vehicle selection (LNP, electroporation, lipofection) is at the discretion of the end user and should be optimised for the target cell type and application.\u003c\/p\u003e\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eTumour-associated antigens (TAAs) are proteins overexpressed or aberrantly presented on malignant cells compared to normal tissue, making them attractive targets for immunotherapy including CAR T-cell therapy, antibody-drug conjugates (ADCs), and bispecific T-cell engagers (BiTEs). Delivering TAA-encoding mRNA allows transient surface expression of the native antigen in human cell lines, supporting antibody epitope mapping, CAR construct validation, and target density quantification by flow cytometry. This format is particularly useful in early-stage target engagement studies where stable cell line generation would be time-prohibitive.\u003c\/p\u003e\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eCAR T-cell target density optimisation: mRNA dose titration enables construction of a target density gradient on cell surfaces, allowing measurement of CAR T-cell activation thresholds.\u003c\/li\u003e\n  \u003cli\u003eADC payload efficiency: Surface antigen expression via mRNA in cytotoxicity reporter cells supports evaluation of ADC internalisation efficiency and payload release kinetics.\u003c\/li\u003e\n  \u003cli\u003eBispecific T-cell engager (BiTE) studies: TAA mRNA-expressing target cells are used in BiTE-mediated T-cell redirected killing assays to determine antibody concentration-activity relationships.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eCAR T activation threshold studies — titrated mRNA expression creates antigen density gradients to determine the minimum antigen density required for CAR T-cell activation.\u003c\/li\u003e\n  \u003cli\u003eADC internalisation assays — mRNA-expressed TAA enables quantification of antibody internalisation rates essential for ADC payload delivery efficiency studies.\u003c\/li\u003e\n  \u003cli\u003eBiTE redirected killing assays — TAA-positive target cells support T-cell redirected killing measurement for bispecific T-cell engager dose-response characterisation.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eValidate target antigen surface expression by flow cytometry with a clinically relevant antibody clone before using in CAR T functional assays to confirm antigen density is within the expected therapeutic range.\u003c\/li\u003e\n  \u003cli\u003eGPC3, PSMA, and HER3 may undergo post-translational modifications (N-glycosylation, GPI anchor addition) in the expression cell line; choose a cell line with the relevant processing machinery for the intended assay.\u003c\/li\u003e\n  \u003cli\u003eInclude antigen-negative control cells (same cell line, non-target mRNA transfected) in all killing and binding assays to distinguish antigen-specific from bystander activity.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"GenCefe Biotech","offers":[{"title":"20 ug","offer_id":53239633248621,"sku":"IR0059002","price":279.0,"currency_code":"USD","in_stock":true},{"title":"100 ug","offer_id":53239651041645,"sku":"IR0059010","price":339.0,"currency_code":"USD","in_stock":true},{"title":"200 ug","offer_id":53239651074413,"sku":"IR0059020","price":399.0,"currency_code":"USD","in_stock":true},{"title":"500 ug","offer_id":53239651107181,"sku":"IR0059050","price":459.0,"currency_code":"USD","in_stock":true},{"title":"1 mg","offer_id":53239651139949,"sku":"IR0059100","price":549.0,"currency_code":"USD","in_stock":true},{"title":"5 mg","offer_id":53239651172717,"sku":"IR0059500","price":1799.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/mRNA_66db8788-aedc-458a-bd5a-1072a1513c24.png?v=1776677730","url":"https:\/\/www.ebiohippo.com\/products\/gpc3-bhn20152504","provider":"BioHippo","version":"1.0","type":"link"}